Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 13.07 -0.24 (-1.8%) Market Cap: 1.12 Bil Enterprise Value: 710.08 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 32/100

Q3 2019 Syndax Pharmaceuticals Inc Earnings Call Transcript

Nov 07, 2019 / 09:30PM GMT
Release Date Price: $6.96 (-0.43%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Syndax Third Quarter 2019 Financial Results Conference Call. (Operator Instructions) And as a reminder, this conference call may be recorded.

I would now like to turn the conference over to your host today, Ms. Melissa Forst with Argot Partners.

Melissa Forst
Argot Partners, LLC - VP

Thank you, operator. Welcome, and thank you to those of you joining us on the line and the webcast this afternoon for a review of Syndax' third quarter 2019 financial and operational results.

I'm Melissa Forst with Argot Partners. And with me this afternoon to discuss the results and provide an update on the company's progress are Dr. Briggs Morrison, Chief Executive Officer; and Rick Shea, Chief Financial Officer. Also joining us on the call today for the question-and-answer session is Michael Metzger, President and Chief Operating Officer; and Dr. Michael Meyers, Chief Medical Officer.

This call is being accompanied by a slide deck that has been posted on the company's website. I would ask you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot